Background: The aim of the study was to test the clinical efficacy and toxicity profile of gemcitabine (GEM) in combination with cisplatin (CDDP) in a series of patients affected by unresectable and/or metastatic biliary tree carcinoma (BTC) previously untreated with chemotherapy.
introduction
In the Western world biliary tract carcinomas (BTC) show a low incidence, which ranges from two to six cases per 100 000/year with a slight prevalence of gallbladder neoplasms over tumors of the bile ducts [1] [2] [3] . The incidence of BTC is higher in females than in males with a 3:1 ratio [1] [2] [3] . BTC include malignant neoplasms that arise from the epithelium of the gall-bladder or anywhere in the intra-hepatic or extra-hepatic bile ducts, i.e. cholangiocarcinoma. BTC are often diagnosed at an advanced/ metastatic stage and, therefore, are not amenable for curative radical surgery [4] . In many cases surgical intervention or percutaneous/endoscopic procedures are carried out for palliative reasons due to the occurrence of rapidly increasing jaundice and/or severe nutritional impairment [5, 6] . Patients with unresectable disease have a very poor prognosis, and even after curative resection the 5-year survival rates are quite low ranging from 0% to 35% for both gall-bladder carcinoma and cholangiocarcinoma [1] [2] [3] [4] [5] [6] .
Despite continuous progress in the search of new active antineoplastic drugs clinical experience with palliative chemotherapy (CT) for BTC is quite scarce in medical literature [4, 8] . So far results of CT have been quite disappointing at least in terms of objective tumor regressions. No major objective responses have been reported for many compounds such as uracil/tegafur and paclitaxel [9, 10] , while cisplatin (CDDP), mitomycin C and modulated 5-fluoruracil (5-FU) have shown response rates ranging from 10% to 20% [11] [12] [13] [14] . Recently the combination of CDDP and 5-FU modulated by folinic acid obtained better results than 5-FU alone in terms of overall response rate (ORR; 19% versus 7%) and survival (OS; 8 versus 5 months), but the difference was not statistically significant [15] . The combination treatment was demonstrated to be less tolerated with more grade 3-4 neutropenia (26% versus 4%) and thrombocytopenia (7% versus 0%).
There is an obvious need for new active drugs and for new combination regimens to improve objective ORR and OS in patients with advanced BTC. In the last decade gemcitabine (GEM), a new nucleoside analogue drug, has been reported to be active against advanced pancreatic adenocarcinoma and BTC at least in terms of ORR [16, 17] . A recent systematic review of a total of 13 single-arm phase II trial reports showed that GEM is a reasonable alternative to best supportive care (BSC) in patients with BTC not amenable for surgery even if a formal comparative trial is lacking [18] . GEM and CDDP revealed synergism in preclinical models [19] and this combination [17] was employed in the treatment of pancreatic cancer with better results than GEM alone at least in terms of ORR and time-toprogression [TTP] .
Based on the above-reported data a multicenter phase II trial was carried out to evaluate the clinical activity of GEM in combination with CDDP in a series of patients with advanced/ metastatic BTC not more amenable with surgery and/or radiotherapy (RT).
patients and methods inclusion criteria
Prior to the entry into this phase II trial all patients had to fulfill the following eligibility criteria: histologically confirmed diagnosis of advanced/ metastatic BTC not more amenable with surgery and/or RT; age ‡18 years; performance status (PS) of 0-2 according to the Eastern Cooperative Oncology Group (ECOG) criteria; life-expectancy of at least 3 months; presence of measurable disease according to the WHO criteria [22] ; no previous CT or RT on the indicator lesion; a 3-4 week interval between the last therapeutic procedure and start of CT; adequate bone marrow function (WBC ‡4000/mm 3 , PLT ‡120 000/mm 3 , Hb ‡10 g%), renal tests (BUN £50 mg%; serum creatinine £1.2 mg%) and liver function (total serum bilirubin <2 mg%, serum transaminases less than twice the normal value). Patients were also required to satisfy the following exclusion criteria: absence of a medical history of prior or concomitant other malignancy with the exception of adequately managed in situ uterine carcinoma or cutaneous basal cell carcinoma; absence of uncontrolled, severe cardio-vascular, neurological, metabolic or infectious diseases; and geographic accessibility to the participating oncology centers in order to guarantee a correct follow-up. Informed consent was required by all patients according to the single institutions guidelines.
disease evaluation
Before starting CT patients were extensively staged in order to identify disease extension as precisely as possible. Therefore, all patients were staged with medical history, physical examination, hemocromocytometric analysis, serum chemistry tests, chest X-rays, ECG, abdominal sonograms, 99Tc bone scan, and serum Cea and Ca 19.9. CT scan or NMR of the abdomen and/or other involved organs was mandatory in all cases. Endoscopy was employed as needed.
evaluation of efficacy
Enrolled patients were first assessed for objective response after three cycles of CT according to the WHO criteria [22] . Briefly, a complete response (CR) was defined as the complete disappearance of all measurable lesions for at least 4 weeks; a partial response (PR) was defined as a ‡50% reduction in the sum of the products of the two major perpendendicular diameters of all measurable tumoral lesions for at least 4 weeks without the appearance of any new metastatic lesion; stable disease (SD) as a <50% reduction or <25% increase in the size of measurable lesions; and progressive disease (PD) as the occurrence of any new metastatic deposit and/or a ‡25% increase in the size of known metastases. Toxicity was recorded according to the NCI Common Toxicity Criteria.
treatment plan
Patients received GEM 1000 mg/m 2 given i.v. diluted in 250 ml of normal saline over 60 min on days 1 and 8 every 3 weeks and CDDP 75-80 mg/m 2 with a standard hydration protocol and forced diuresis with mannitole. All patients received an anti-emetic protocol with anti-HT3 drugs and dexamethasone both given i.v. 20 min before CT. Duration of CT was dependent on clinical response. In case of CR, PR or SD after the first three cycles patients were given another three cycles of CT and then further restaged. In the case of persistent response or stable disease, CT was continued for a further three cycles in the absence of unacceptable toxicity.
In the case of PD detected both clinically and/or radiologically, CT was withheld. CT was delivered if WBC ‡2500/mm 3 or absolute neutrophil count ‡1000/mm 3 and PLT ‡100 000/mm 3 . If WBC, ANC or PLT were under the above reported values CT was delayed by 1 week and subsequent doses of GEM reduced to 800 mg/m 2 . In the case of hepatic toxicity ‡grade 2 GEM dosage was reduced to 500-800 mg/m 2 depending on the severity of side-effects. The occurrence of any grade 4 toxicity, with the exception of febrile neutropenia, resulted in patients' drop out. If on the day of planned GEM hematological or hepatic recovery was not sufficient then CT was delayed by 1 week.
study design and statistics
The primary end points of this trial were ORR and toxicity. Secondary end points included TTP and OS. Simon's optimal two-stage design was used for calculation of the sample size. With a 5% alpha risk and a power of 0.90, we determined a first-stage response probability of 10% (which, if true, implied discontinuing the trial) and a minimal rate of efficacy of 30% (which, if true, implied moving on to the second stage of the trial). More than three responses in 18 evaluable patients were required to pass to the second phase of enrolment up to 35 patients. Objective responses were reported as relative rates with their 95% confidence intervals (CI).
Comparisons between groups were carried out applying a chi-square test to a contingency table. TTP was calculated from the date of first cycle of CT until the date when PD was documented, while OS was calculated from the date of starting CT until death or last documented follow-up. Both analysis and curves were carried out according to the product limit method of Kaplan and Meier employing statistical software [23] .
results
patient population
Thirty-eight consecutive patients with inoperable and/or metastatic BTC were enrolled into the trial. All patients fulfilled the required eligibility criteria. The main clinical and demographical characteristics of enrolled patients are depicted in Table 1 . Briefly, there were six males (16%) and 32 females (84%) with a median age of 61 years and a median PS of 1. Primary tumor sites included gall-bladder in 10 cases (26%) and bile duct carcinoma in 28 (74%). Sites of disease at entry were locoregional disease or recurrence in 47% of cases, liver metastases in 84%, lymphonodes in 45%, peritoneum in 5% and symposium article 
clinical activity
All enrolled patients were included in response evaluation since assessment of objective response was carried out according to an intent-to-treat fashion. Two patients did not complete the first three cycles of CT programmed before re-evaluation due to clinically evidenced PD. One patient was not evaluable. These three patients were considered as treatment failures and included in the PD subgroup. A CR was achieved in one patient (3%) with a duration of 8 months. A PR was recorded in 11 cases (29%; 95% CI 6% to 48%) with a median duration of 6.4 months (range 5-11 months) for an ORR of 32%. SD was seen in eight cases (21%), while the remaining 18 patients showed PD. Tumor growth control rate was 53%. Objective responses were recorded at locoregional disease, liver and nodal metastases. Lung and peritoneal metastases did not respond. Two patients with tumor-related hypogastric pain were given antalgic RT after CT withdrawal. TTP was 4 months (range 2-11 months) and median OS was 8+ months (range 2-15 months).
toxicity
The main side-effects are reported in Table 3 according to the NCI Common Toxicity Criteria. No toxic deaths were recorded and in no case was CT withdrawn due to toxicity. Most sideeffects, such as gastrointestinal toxicity, were rather mild with less than 5% hematological grade 4 toxicity. Hematological toxicity was the most frequently reported side-effect. Three patients had fever due to infection without severe grade 4 neutropenia. Flu-like syndrome was recorded in 21% of patients. Reversible grade 1-2 liver toxicity was recorded in nine cases (23%).
discussion
BTC are among the most aggressive malignancies with a very poor prognosis. Most BTC will have grown beyond the limits of curative resection by the time they become clinically evident [24] . Despite dismal results achieved with CT even with newer drugs [25] , a positive role of CT in the management of advanced BTC has been suggested by the data reported by Glimelius et al. [26] . These authors carried out a phase III trial in which 90 patients with advanced pancreatic adenocarcinoma or BTC were randomized to receive BSC or CT with modulated 5-FU and etoposide plus BSC. OS and quality of life-adjusted survival were longer in the CT group with a statistically significant difference. Moreover, patients treated with CT had a better quality of life for a minimum period of 4 months compared with the BSC group. However, statistical significance was lost if patients with BTC were analyzed independently of patients with pancreatic carcinoma. Although these data may not be considered definitive, due to the relatively small size of the patients population, the low power of the study and the inclusion of patients with both pancreatic and BTC in the same trial, they have strengthened the search for new active drugs and better combination regimens. To date there is no agreement on the best regimen for advanced BTC and most regimens have been based on 5-FU, which has been largely employed both as a single agent or in modulation with other drugs.
In this paper we report the activity and toxicity panel of a combination of GEM and CDDP in a series of 38 patients with advanced BTC. In our hands this regimen yielded a 32% ORR with a tumor growth control rate of 53% with acceptable toxicity in most patients. As shown in Table 4 the results reported in the present study are consistent with those reported by others in the literature [27] [28] [29] [30] [31] . With the exception of the paper of Malik et al. [25] including a very small number of patients, other adequately sized phase II studies report an ORR of 27%-36%. Doval et al. reported a 37% ORR with a median OS of 5 months in a series of 30 consecutive patients with grade 3-4 neutropenia and anemia in 16% and 36% of cases, respectively [26] . A 27% ORR was reported by Thongpraset et al. [27] in 40 patients who showed a median OS of 9 months. Side-effects were mainly represented by mucosal and hematological toxicity, but the incidence of grade 3-4 toxicity was minimal with no treatment withdrawals due to toxicity. Kim et al. [29] published a phase II study on 29 patients treated with GEM 1250 mg/m 2 on days 1 and 8 and CDDP 75 mg/m 2 on day 1, every 3 weeks. The reported ORR was 34% with a median OS of 11 months. However, in these clinical studies data concerning survival are very difficult to interpret due to the relatively small number and the considerable variability of clinical characteristics of enrolled patients.
Even if the size of these studies and the regimen employed make it difficult to draw significant conclusions on the role of such drugs in the management of advanced BTC, the acceptable toxicity profile and good tolerability of the GEM/CDDP regimen should be considered when a treatment choice is to be made. Overall, the results reported for the GEM/CDDP regimen compare well to those achieved with other GEM-based combination such as those with 5-FU [19, 32] .
In conclusion, data reported in this phase II trial demonstrate that the combination of GEM and CDDP is active against advanced, unresectable, recurrent and/or metastatic BTC with a good tolerability and few manageable side-effects. Although no definitive conclusion on survival or activity may be inferred from the above-reported data due to the non-comparative nature of this study, the GEM/CDP regimen represents a reasonable choice for palliation if advanced BTC.
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